Figure 3
Figure 3. TMPro mice have a shifted thrombin-aPC signaling balance in systemic inflammation. (A) Plasma TAT and IL1β levels 18 hours after LD50 LPS challenge of TMPro and TMPro/PAR1−/− mice; the indicated treatments were given at 10 hours after LPS (mean ± SD; n = 4/group; * indicates different from respective control; P < .02 by ANOVA). (B,C) Survival of LD50 LPS-challenged TMPro (B) or TMPro/PAR1−/− (C) mice following treatment by a single bolus injection of the indicated agents at 10 hours (n = 8–15/group; P < .001 for aPC5A vs TMPro control).

TMPro mice have a shifted thrombin-aPC signaling balance in systemic inflammation. (A) Plasma TAT and IL1β levels 18 hours after LD50 LPS challenge of TMPro and TMPro/PAR1−/− mice; the indicated treatments were given at 10 hours after LPS (mean ± SD; n = 4/group; * indicates different from respective control; P < .02 by ANOVA). (B,C) Survival of LD50 LPS-challenged TMPro (B) or TMPro/PAR1−/− (C) mice following treatment by a single bolus injection of the indicated agents at 10 hours (n = 8–15/group; P < .001 for aPC5A vs TMPro control).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal